<DOC>
	<DOCNO>NCT00305682</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fludarabine cyclophosphamide , work different way stop growth cancer cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill cancer cell . An umbilical cord blood transplant may able replace blood-forming cell destroy chemotherapy radiation therapy . Sometimes transplanted cell donor make immune response body 's normal cell . Giving sirolimus mycophenolate mofetil transplant may stop happen . PURPOSE : This phase II trial study well give fludarabine cyclophosphamide together total-body irradiation follow umbilical cord blood transplant , sirolimus , mycophenolate mofetil work treat patient hematologic cancer .</brief_summary>
	<brief_title>Non-Myeloablative Conditioning Unrelated Donor Umbilical Cord Blood Transplant</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine one- two-year survival patient hematologic malignancy treat nonmyeloablative conditioning regimen comprise fludarabine , cyclophosphamide , total-body irradiation follow umbilical cord blood transplantation post-transplant immunosuppression comprise sirolimus mycophenolate mofetil . Secondary - Determine six-month nonrelapse mortality patient treat regimen . - Determine presence chimerism patient treat regimen day 21 , 60 , 100 , 180 , 365 . - Determine incidence neutrophil engraftment day 42 patient treated regimen . - Determine incidence platelet engraftment six month patient treat regimen . - Determine incidence grade II-IV grade III-IV acute graft-versus-host disease ( GVHD ) day 100 patient treated regimen . - Determine incidence chronic GVHD one year patient treat regimen . - Determine probability overall survival within one two year patient treat regimen . - Determine probability progression-free survival within one two year patient treat regimen . - Determine incidence relapse disease progression within one two year patient treat regimen . OUTLINE : This nonrandomized study . Patients stratify five disease group : 1. acute myeloid leukemia , myelodysplastic syndrome , chronic myelogenous leukemia [ CML ] first chronic phase second chronic phase [ CP2 ] myeloid blast crisis ; 2. acute lymphoblastic leukemia , Burkitt 's lymphoma , CML CP2 post lymphoid blast crisis , 3. large-cell B T-cell lymphoma , mantle cell lymphoma ; 4. chronic lymphocytic leukemia/small lymphocytic lymphoma , prolymphocytic leukemia , marginal zone B-cell lymphoma , follicular lymphoma ; 5 . Hodgkin 's lymphoma multiple myeloma . - Nonmyeloablative conditioning : Patients receive fludarabine intravenously day -6 -2 cyclophosphamide IV day -6 . Patients undergo prior autologous transplant receive ≤ 1 course prior multiagent chemotherapy severely immunosuppressive therapy past 3 month also receive anti-thymocyte globulin IV day -6 -4 . All patient also undergo total-body irradiation day -1 . - Umbilical cord blood transplant : Patients undergo umbilical cord blood transplantation day 0 . - Post-transplant immunosuppression : Sirolimus administer start day -3 8mg-12mg mg oral load dose follow single dose 4 mg/day target serum concentration 3 12 mg/mL . Levels monitor 3 times/week first 2 week , weekly day +60 , clinically indicate day +100 post-transplantation . In absence acute GVHD sirolimus may taper start day +100 eliminate day +180 post-transplantation . Patients also receive mycophenolate mofetil IV day -3 5 orally day 6-30 . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 320 patient accrue study .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Age , Graft Cell Dose Graft HLA Criteria Subjects must &lt; 70 year old . Subjects age ≥ 70 ≤ 75 may eligible CoMorbidity Scoring ( HCTCI ) score ≤ 2 . The UCB graft match 46 HLAA , B , DRB1 antigens recipient . Patients coenrolled MT200601 Phase I Study Infusion Umbilical Cord Blood Derived CD25+CD4+ TRegulatory ( Treg ) Cells NonMyeloablative Cord\Blood Transplantation receive graft compose 2 UCB unit . Disease Criteria : Acute Leukemias : Acute myeloid leukemia : high risk complete remission 1 ( CR1 ) ( evidence precede myelodysplastic syndrome ( MDS ) , high risk cytogenetics associated MDS complex karyotype , &gt; 2 cycle obtain CR erythroblastic megakaryocytic ) ; second great CR . Acute lymphoblastic leukemia/lymphoma : high risk CR1 evidence high risk cytogenetics ( e.g . ( 9 ; 22 ) , ( 1 ; 19 ) , ( 4 ; 11 ) , myeloid/lymphoid mixed lineage leukemia [ MLL ] rearrangement , hypodiploidy Ikaros family zinc finger 1 [ IKZF1 ] ) , &gt; 1 cycle obtain CR evidence minimal residual disease ( MRD ) . Patients second great CR also eligible . Burkitt 's lymphoma CR2 subsequent CR Natural Killer cell malignancy Chronic myelogenous leukemia : type except refractory blast crisis . Chronic phase patient must fail intolerant Gleevec Myelodysplastic syndrome : Largecell lymphoma , Hodgkin lymphoma multiple myeloma chemotherapy sensitive disease fail patient ineligible autologous transplant . Chronic lymphocytic leukemia/small lymphocytic lymphoma ( CLL/SLL ) , marginal zone Bcell lymphoma , follicular lymphoma , progress within 12 month achieve partial complete remission . Patients remission last &gt; 12 month , eligible least two prior therapy . Patients bulky disease consider debulking chemotherapy transplant . Patients refractory disease eligible , unless bulky disease estimate tumor double time le one month . Lymphoplasmacytic lymphoma , mantlecell lymphoma , prolymphocytic leukemia eligible initial therapy chemotherapy sensitive . Refractory leukemia MDS . Bone marrow failure syndrome , except Fanconi Anemia Myeloproliferative syndromes Patients undergone autologous transplant &gt; 12 month prior allogeneic transplantation Adequate Organ Function Performance Status &lt; 70 year available 56/6 HLAA , B , DRB1 match sibling donor Pregnancy breastfeed Evidence human immunodeficiency virus ( HIV ) infection know HIV positive serology Current active serious infection Unless postchemotherapy radioimmunoconjugated antibody induced aplasia , he/she would eligible Arm 3 , patient acute leukemia morphologic relapse/ persistent disease define &gt; 5 % blast normocellular bone marrow OR % blast blast unique morphologic marker ( e.g . Auer rod ) associate cytogenetic marker allow morphologic relapse distinguish eligible . Chronic myelogenous leukemia ( CML ) refractory blast crisis Large cell lymphoma , mantle cell lymphoma Hodgkin disease progressive salvage therapy . Stable disease acceptable move forward provide nonbulky . Active central nervous system malignancy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>